Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Hideo Kunimoto"'
Autor:
Takanobu Iwadare, Takefumi Kimura, Taiki Okumura, Shun-ichi Wakabayashi, Taro Nakajima, Shohei Kondo, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Naoyuki Fujimori, Tomoo Yamazaki, Hideo Kunimoto, Satoshi Shimamoto, Koji Igarashi, Satoru Joshita, Naoki Tanaka, Takeji Umemura
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-9 (2024)
Abstract Background Circulating autotaxin (ATX) levels have been reported to correlate with liver inflammation activity and liver fibrosis severity in patients with non-alcoholic fatty liver disease (NAFLD). The objective of this study is to investig
Externí odkaz:
https://doaj.org/article/7bd204aa7e9f4f2cbac9920231994507
Autor:
Takanobu Iwadare, Takefumi Kimura, Hideo Kunimoto, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Naoki Tanaka, Takeji Umemura
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
AimShort-term use of pemafibrate (PEM), a selective modulator of peroxisome proliferator-activated receptor alpha, has been reported to improve abnormal liver function in patients with nonalcoholic fatty liver disease with hypertriglyceridemia (HTG-N
Externí odkaz:
https://doaj.org/article/a1f84d912d96457280986941cd66bf83
Autor:
Takanobu Iwadare, Takefumi Kimura, Hideo Kunimoto, Naoki Tanaka, Shun-ichi Wakabayashi, Tomoo Yamazaki, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Satoru Joshita, Takeji Umemura
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2806 (2022)
Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors
Externí odkaz:
https://doaj.org/article/3d186cd5093e4b09bd64029b1ab4327c
Autor:
Keiji Yokoyama, Ryo Yamauchi, Kumiko Shibata, Hiromi Fukuda, Hideo Kunimoto, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka
Publikováno v:
Clinical and Molecular Hepatology, Vol 25, Iss 2, Pp 183-189 (2019)
Background/Aims There is a controversy about the availability of invasive treatment for esophageal/gastric varices in patients with Child-Pugh class C (CP-C) end-stage liver cirrhosis (LC). We have evaluated the validity of invasive treatment with CP
Externí odkaz:
https://doaj.org/article/5afade5d30c74ddead620fb32d0b944b
Autor:
Hiromi Fukuda, Kazuhide Takata, Takanori Kitaguchi, Ryo Yamauchi, Hideo Kunimoto, Takashi Tanaka, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Ai Mogi, Shinichi Kora, Kaori Koga, Morishige Takeshita, Kengo Yoshimitsu, Shotaro Sakisaka
Publikováno v:
Case Reports in Hepatology, Vol 2018 (2018)
Patients with autoimmune hepatitis (AIH) may sometimes have concomitant idiopathic thrombocytopenic purpura (ITP). Severe thrombocytopenia in ITP interferes with percutaneous liver biopsy for pathological diagnosis of AIH. Here, we report a case of A
Externí odkaz:
https://doaj.org/article/b1ab4eea5cd9403481c7491a94b413d8
Autor:
Takanobu Iwadare, Takefumi Kimura, Yusuke Nagata, Hiroshi Suzuki, Hideo Kunimoto, Hiroyuki Kitabatake, Ayako Seki, Yasuhide Ochi, Etsuo Hara, Takeji Umemura
Publikováno v:
Clinical Journal of Gastroenterology. 16:372-376
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6971a55bf8ddb2533adbe1ab33b2362
https://doi.org/10.1007/s12328-023-01770-5
https://doi.org/10.1007/s12328-023-01770-5
Autor:
Kazuhide Takata, Takashi Tanaka, Akira Anan, Atsushi Fukunaga, Takahiro Nagata, Hiromi Fukuda, Ryo Yamauchi, Hideo Kunimoto, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Kaoru Iwata, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Publikováno v:
Oncology. 100:303-312
Background and Aims: Radiofrequency ablation (RFA) has replaced percutaneous ethanol injection (PEI) as the treatment of choice for hepatocellular carcinoma (HCC); however, control of local tumor progression (LTP) remains a challenge in perivascular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08227fe090969a4f4578b66b582d8a8a
https://doi.org/10.1159/000522374
https://doi.org/10.1159/000522374
Autor:
Makiko Matsumura, Michiharu Komatsu, Hiroyuki Kobayashi, Takanobu Iwadare, Takeji Umemura, Natsuko Kobayashi, Sachie Ozawa, Yuki Yamashita, Satoru Joshita, Yosuke Yamada, Soichiro Shibata, Hiromi Saito, Chiharu Miyabayashi, Ayumi Sugiura, Shun-Ichi Wakabayashi, Hideo Kunimoto, Naoyuki Fujimori, Yuichi Nozawa, Tomoo Yamazaki, Taiki Okumura
Publikováno v:
Hepatology Research. 51:933-942
AIMS Hepatocellular carcinoma (HCC) can still occur in hepatitis C virus (HCV) patients who have achieved a sustained virologic response (SVR), which remains an important clinical issue in the direct-acting antivirals era. The current study investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98715546b16c16bd3260fb7c0691c824
https://doi.org/10.1111/hepr.13689
https://doi.org/10.1111/hepr.13689
Autor:
Atsushi Fukunaga, Yasuaki Takeyama, Daisuke Morihara, Keiji Yokoyama, Fumihito Hirai, Kazuhide Takata, Kaoru Umeda, Takashi Tanaka, Hideo Kunimoto, Sho Fukuda, Hiromi Fukuda, Shotaro Sakisaka, Kunitoshi Sakurai, Ryo Yamauchi, Satoshi Shakado, Makoto Irie
Publikováno v:
Internal Medicine
An 88-year-old man was admitted for elevated liver enzyme levels. Nine years earlier, the patient had been diagnosed with diffuse large B-cell lymphoma (DLBCL) and undergone rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, prednisone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e6bddfd1ae9b05b091474a13009e48
https://doi.org/10.2169/internalmedicine.3805-19
https://doi.org/10.2169/internalmedicine.3805-19
Autor:
Keiji Yokoyama, Kazuhide Takata, Hideo Kunimoto, Hiromi Fukuda, Fumihito Hirai, Naoaki Tsuchiya, Satoshi Shakado, Takashi Tanaka, Daisuke Morihara, Ryo Yamauchi, Shotaro Sakisaka, Yasuaki Takeyama
Publikováno v:
Oncology. 98:779-786
Background and Aims: Lenvatinib is an oral anticancer drug for patients with unresectable advanced hepatocellular carcinoma (HCC). We evaluated whether a reduction in tumor stain at 2 weeks after lenvatinib treatment in patients with unresectable HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed61642d9578dce1143035cc659abdf3
https://doi.org/10.1159/000509005
https://doi.org/10.1159/000509005